GLUE stock icon

Monte Rosa Therapeutics
GLUE

$6.48
3.68%

Market Cap: $398M

0
Funds holding %
of 6,728 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

320% more call options, than puts

Call options by funds: $374K | Put options by funds: $89K

146% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 13

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

9% more funds holding

Funds holding: 68 [Q1] → 74 (+6) [Q2]

4.7% less ownership

Funds ownership: 79.66% [Q1] → 74.96% (-4.7%) [Q2]

39% less capital invested

Capital invested by funds: $282M [Q1] → $171M (-$110M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
70%
upside
Avg. target
$14.67
126%
upside
High target
$17
162%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
Robert Driscoll
56% 1-year accuracy
38 / 68 met price target
70%upside
$11
Outperform
Reiterated
12 Sept 2024
Wells Fargo
Derek Archila
69% 1-year accuracy
20 / 29 met price target
162%upside
$17
Overweight
Maintained
12 Aug 2024
Piper Sandler
Edward Tenthoff
46% 1-year accuracy
18 / 39 met price target
147%upside
$16
Overweight
Reiterated
28 Jun 2024

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical data expected in Q1 2025 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrated a favorable safety and pharmacodynamic profile at 0.5 mg with a 21 days on/7 days off schedule; dosing ongoing at 0.75 mg using a 21/7 schedule; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 Achieved first program and financial milestones from strategic research collaboration with Roche Strong cash position expected to fund operations into H1 2027 and through multiple anticipated clinical readouts including from proof-of-concept patient studies for MRT-2359, MRT-6160, and MRT-8102 BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) --   Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the second quarter that ended June 30, 2024. “The IND clearance of our VAV1-directed MGD MRT-6160 represents a major corporate milestone for Monte Rosa, signifying what we believe to be the first clinical-stage, rationally designed MGD for a non-oncology indication,” said Markus Warmuth, M.D.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update